कंपनी का अवलोकन
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of small molecule therapeutics that selectively degrade disease-causing proteins by utilizing the body's endogenous protein degradation systems. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, where its primary objective involves advancing novel therapeutic modalities to address unmet medical needs through targeted protein degradation mechanisms. As of the latest reported data, the company possesses a market capitalization of $7.13B and employs 238 individuals, while reporting a Trailing Twelve Months (TTM) revenue of $39.21M. These valuation and operational metrics indicate that despite the company's significant market cap relative to its annual revenue, Kymera maintains a substantial asset base and human capital investment characteristic of capital-intensive biotechnology firms in the clinical development phase. The disparity between the $7.13B market cap and the $39.21M revenue suggests that the market price incorporates significant expectations regarding future clinical trial outcomes and potential regulatory approvals for its pipeline assets, including the development of KT-621, an oral STAT6 inhibitor.
वित्तीय स्वास्थ्य
Kymera Therapeutics reported a revenue of $39.21M for the trailing twelve months, yet it recorded a net income of $-311,351,008, revealing a substantial gap between top-line growth and bottom-line profitability that underscores the high cost structure inherent in clinical-stage biotechnology operations. The company generated an EBITDA of $-338,831,008, which further highlights the intensive cash burn rates associated with research and development activities prior to commercial product launch. Free cash flow stood at $-136,041,248, indicating that the company is consuming cash to fund its operations and development programs rather than generating surplus liquidity from its core business activities. The financial margins reflect this developmental stage, with a gross margin of 0.0%, an operating margin of -3411.0%, and a profit margin of 0.0%, all of which point to a business model currently prioritizing asset building over current period profitability. In terms of liquidity and leverage, the company holds $848.28M in cash against total debt of $82.25M, resulting in a debt-to-equity ratio of 5.21. Although the debt-to-equity ratio appears elevated numerically, the massive cash reserve suggests the balance sheet is not leveraged in a distress manner but rather positioned to sustain long-term R&D expenditures. The current ratio is an exceptionally high 10.47, which indicates robust short-term liquidity and a strong ability to cover current liabilities with existing current assets. Return on Equity stands at -25.8% and Return on Assets at -15.9%, metrics that reveal the company is currently generating negative returns on its capital base due to the lack of commercial revenue, a typical characteristic for clinical-stage entities reinvesting all earnings into growth initiatives.
मूल्यांकन आकलन
Valuation metrics for Kymera present a complex picture due to the absence of positive earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -21.79. The difference between the non-existent trailing P/E and the negative forward P/E implies that the market is valuing the company based on future potential rather than historical or current earnings performance, relying instead on projected cash flows and milestone achievements. The price-to-book ratio is recorded at 4.50, indicating that the market values the company at a significant premium over its net asset book value, reflecting confidence in the intrinsic value of its intellectual property and pipeline assets. Alternative valuation measures such as the price-to-sales ratio of 181.87 and an EV/EBITDA of -18.79 suggest that the market is pricing in high expectations for revenue expansion and successful commercialization of its drug candidates. The stock price has fluctuated significantly over the past year, trading between a 52-week high of $103.00 and a 52-week low of $19.45, and the current market price sits at a level that reflects recent volatility but remains well below the previous yearly peak. The beta value is 2.29, which means the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the S&P 500 index during periods of market stress or growth.
Growth & Income
Revenue growth year-over-year declined by 61.2%, while earnings growth is N/A due to the company's ongoing losses, illustrating that the revenue contraction is a result of standard operational scaling or strategic spending adjustments rather than a fundamental business collapse. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all of its earnings to reinvest into research and development rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company follows a growth-oriented capital allocation strategy, directing all available funds toward advancing its clinical pipeline and expanding its operational capabilities. Overall, Kymera Therapeutics presents a profile of negative growth in recent revenue figures and no income distribution, which is consistent with the capital-intensive nature of clinical-stage biotechnology companies that rely on external capital or internal cash reserves to fund future expansion and commercialization efforts.